Posted by Michael Wonder on 27 Jul 2019
Australian study evaluates real world evidence of Botox to prevent migraine
26 July 2019 - OnabotulinumtoxinA has been approved by Australia’s reimbursement mechanism for medicines, the PBS, for preventive treatment of headaches in patients with chronic migraine,
Researchers conducted a study to evaluate real-world evidence of onabotulinumtoxinA.
Medical records of adults with inadequately controlled chronic migraine who received PBS-subsidised onabotulinumtoxinA for the first time, starting in March 2014, were evaluated. The percentage of patients reaching a response of 50% or greater reduction in headaches from baseline after 2 treatment cycles was the primary measure of the research. Patient demographics, headache severity, and Headache Impact Test were among the many characteristics considered.
